Role of human innate immune mutations in loss of tolerance to Borrelia burgdorferi
人类先天免疫突变在伯氏疏螺旋体耐受性丧失中的作用
基本信息
- 批准号:10256713
- 负责人:
- 金额:$ 59.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-08 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAmino AcidsAnimalsAntibiotic TherapyArthritisBacteriaBeliefBiological AssayBorrelia burgdorferiCarditisCell DeathCell LineCell surfaceCellsClinicalCollaborationsConfocal MicroscopyDangerousnessDataDefectDevelopmentDiseaseExanthemaExhibitsExposure toFailureFatigueGenesHealthHeterodimerizationHourHumanHuman GeneticsHuman InbreedingImmuneImmune ToleranceImmune responseImmune systemImmunologic ReceptorsIn VitroInbred MouseInfectionInflammationInflammatoryInflammatory ResponseInnate Immune SystemIsoleucineKnock-outLaboratoriesLifeLigandsLinkLipoproteinsLocationLyme ArthritisLyme DiseaseMeasuresMediatingMeningitisMetabolismModelingMovementMutationNatural ImmunityNeurocognitiveOrganismPainPathway interactionsPatientsProcessReactionReportingResearch PersonnelRiskRoleSerineSignal PathwaySignal TransductionSignaling MoleculeSingle Nucleotide PolymorphismSiteStimulusSymptomsSyndromeTLR1 geneTLR2 geneTestingTimeUrsidae FamilyVector-transmitted infectious diseaseacute infectioncell typecytokineexperimental studyfluglucose metabolismimmune clearancein vivoindividual patientmacrophagemouse modelmutantpathogenpersistent symptompolarized cellreceptorreceptor expressionresponsetraffickingweapons
项目摘要
The majority of symptoms of Lyme disease are due to the host immune response to the organism, Borrelia
burgdorferi, and resolve over time, even without antibiotic treatment. In its natural host, little or no reaction to
infection can be seen despite the fact that the organism persists for life. In humans and inbred mice (which do
develop immune responses to the organism), inflammation is thought to be initiated by receptors of the innate
immune system. In vitro, loss of innate, pathogen-sensing receptors that recognize B. burgdorferi such as toll-
like receptor 2 (TLR2) results in a decrease inflammatory response. However, in vivo studies of animals
deficient in these receptors or their adaptor molecules do not show reduced inflammation and in many cases
show increased inflammation. Recently, in humans, a single nucleotide polymorphism (SNP) in the tlr1 gene
that results in loss of expression of the receptor on the cell surface was found to be associated with increased
inflammation and symptoms. This suggests that after the initial stimulus, a major role for these innate immune
molecules is in dampening inflammation. One major difference between in vitro studies and the in vivo
infections is that the in vitro experiments are typically conducted by measuring responses minutes to hours
after exposure to the organism. We have evidence that more prolonged exposures in vitro result in the
development of innate immune “tolerance” to stimulation by B. burgdorferi.
In this proposal, we will study the role of the tlr1-1805GG SNP in disrupting innate immune tolerance,
thereby leading to excessive inflammatory responses. The 1805GG SNP results in a loss of localization to the
cell surface but does not affect the activity of the receptor. Therefore, in Aim 1, we will first determine the
effects of the SNP on specific, localization-dependent signaling pathways and downstream cytokine
responses. We have previously shown that the TLR1/TLR2 ligand Pam3CSK4 can initiate signaling from both
intracellular and cell surface locations although the signals are different in each location. It is likely that the tlr1-
1805GG SNP continues to signal endosomally. We will track movements of the receptors and ligands as well
as compare a tlr1 deletion to the tlr1-1805GG SNP. In Aim 2, we will assess the role of the tlr1-1805GG SNP
on macrophage reprogramming leading to loss of innate immune tolerance to B. burgdorferi. We will focus on
understanding its effects on macrophage polarization, cell death and the role of glucose metabolism. Finally, in
Aim 3, using isogenic B. burgdorferi isolates that do or do not initiate tolerance, we will identify the role of
specific components of the organism in moderating macrophage reprograming and loss of tolerance.
We believe that B. burgdorferi infection, where there is prolonged infection with minimal evidence of
inflammation over time, is an excellent model to understand how the immune system can control responses to
invasive bacteria that pose less threat to health than continued efforts to clear the infection—in essence
making the organism an invasive “commensal” through the development of innate immune tolerance.
莱姆病的大多数症状是由于宿主对伯氏疏螺旋体的免疫反应造成的
即使没有抗生素治疗,伯氏杆菌也会随着时间的推移而消退。在其自然宿主中,很少或没有反应
尽管该生物体终生存在,但仍然可以看到感染。在人类和近交系小鼠中(这确实
对生物体产生免疫反应),炎症被认为是由先天性受体引发的
免疫系统。在体外,识别伯氏疏螺旋体的先天病原体感应受体(例如 toll-
样受体 2 (TLR2) 会导致炎症反应减少。然而,动物体内研究
缺乏这些受体或其衔接分子并不能减少炎症,并且在许多情况下
显示炎症增加。最近,在人类中,tlr1 基因中的单核苷酸多态性 (SNP)
导致细胞表面受体表达丧失的结果被发现与增加
炎症和症状。这表明在最初的刺激之后,这些先天免疫发挥了主要作用
分子具有抑制炎症的作用。体外研究与体内研究的一大区别
感染的原因是体外实验通常是通过测量几分钟到几小时的反应来进行的
接触有机体后。我们有证据表明,更长时间的体外暴露会导致
对伯氏疏螺旋体刺激的先天免疫“耐受性”的发展。
在本提案中,我们将研究 tlr1-1805GG SNP 在破坏先天免疫耐受中的作用,
从而导致过度的炎症反应。 1805GG SNP 导致定位丢失
但不影响细胞表面受体的活性。因此,在目标 1 中,我们首先要确定
SNP 对特定的、定位依赖性信号通路和下游细胞因子的影响
回应。我们之前已经证明 TLR1/TLR2 配体 Pam3CSK4 可以启动来自两者的信号传导
细胞内和细胞表面位置,尽管每个位置的信号不同。很可能 tlr1-
1805GG SNP 继续在内体发出信号。我们还将跟踪受体和配体的运动
将 tlr1 缺失与 tlr1-1805GG SNP 进行比较。在目标 2 中,我们将评估 tlr1-1805GG SNP 的作用
巨噬细胞重编程导致对伯氏疏螺旋体失去先天免疫耐受。我们将重点关注
了解其对巨噬细胞极化、细胞死亡的影响以及葡萄糖代谢的作用。最后,在
目标 3,使用能够或不引发耐受性的同基因伯氏疏螺旋体分离株,我们将确定
生物体的特定成分可调节巨噬细胞重编程和耐受性丧失。
我们认为,伯氏疏螺旋体感染存在长期感染,且证据极少。
随着时间的推移,炎症是了解免疫系统如何控制对炎症的反应的绝佳模型。
从本质上讲,与持续努力清除感染相比,入侵细菌对健康的威胁要小
通过先天免疫耐受的发展,使生物体成为侵入性“共生体”。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Linden T Hu其他文献
Case 24-2015
案例24-2015
- DOI:
- 发表时间:
2015 - 期刊:
- 影响因子:0
- 作者:
Linden T Hu;Athe M. N. Tsibris;John A. Branda - 通讯作者:
John A. Branda
Linden T Hu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Linden T Hu', 18)}}的其他基金
Auto-antibodies as predictive markers for Post treatment Lyme Disease Syndrome
自身抗体作为治疗后莱姆病综合征的预测标记
- 批准号:
10737996 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
Laboratory for Combinatorial Drug Regimen Design for Resistant and Emerging Pathogens
耐药和新发病原体组合药物方案设计实验室
- 批准号:
10596722 - 财政年份:2022
- 资助金额:
$ 59.05万 - 项目类别:
Role of human innate immune mutations in loss of tolerance to Borrelia burgdorferi
人类先天免疫突变在伯氏疏螺旋体耐受性丧失中的作用
- 批准号:
10461854 - 财政年份:2020
- 资助金额:
$ 59.05万 - 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
- 批准号:
10397615 - 财政年份:2020
- 资助金额:
$ 59.05万 - 项目类别:
Role of human innate immune mutations in loss of tolerance to Borrelia burgdorferi
人类先天免疫突变在伯氏疏螺旋体耐受性丧失中的作用
- 批准号:
10680556 - 财政年份:2020
- 资助金额:
$ 59.05万 - 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
- 批准号:
10606624 - 财政年份:2020
- 资助金额:
$ 59.05万 - 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
- 批准号:
10165497 - 财政年份:2020
- 资助金额:
$ 59.05万 - 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
- 批准号:
10674121 - 财政年份:2020
- 资助金额:
$ 59.05万 - 项目类别:
Understanding Human Immunological Responses to Ixodes Tick Bites
了解人类对硬蜱叮咬的免疫反应
- 批准号:
9807836 - 财政年份:2019
- 资助金额:
$ 59.05万 - 项目类别:
Coping with Stress: Next Generation Approaches to Borrelia burgdorferi Host Adaptation
应对压力:伯氏疏螺旋体宿主适应的下一代方法
- 批准号:
9892949 - 财政年份:2017
- 资助金额:
$ 59.05万 - 项目类别:
相似海外基金
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 59.05万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 59.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
- 批准号:
2888395 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
- 批准号:
10761044 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
- 批准号:
10728925 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
- 批准号:
10757309 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:














{{item.name}}会员




